Arena Pharmaceuticals
-
Pfizer: $6.7B Arena buyout complements rather than replaces JAK drugs
Sales of blockbuster Pfizer drug Xeljanz are under pressure from a stronger safety warning placed across that drug’s entire class. In acquiring Arena Pharmaceuticals for $6.7 billion, Pfizer gets a lead compound with a different and potentially safer approach to treating inflammatory conditions.
-
Eisai to pull obesity drug after post-marketing study reveals increased cancer risk
The voluntary withdrawal was in response to an FDA request. Eisai said its interpretation of the data differed from the agency’s, but the drug’s original developer had called off pursuit of European approval when regulators there pointed to potential tumor risk from long-term use.
-
Jorie Healthcare CEO Shares Why Automation is Critical to Revenue Cycle Management
The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.
-
Same name, different company: Arena’s new CEO cuts the fat
Ten months in, CEO of Arena Pharmaceuticals Amit Munshi has made some radical changes to the fragmented company, pulling away from its flagship weight loss drug to focus on the clinical pipeline.
-
Does FDA’s approval of first obesity drug in 13 years reflect a policy shift?
The U.S. Food and Drug Administration’s move to approve the first obesity drug in 13 […]
-
Republican wins unlikely to kill health reform law (Morning Read)
Though presumptive House Speaker John Boehner (R-Ohio) says of health reform, “there’s a lot of tricks up our sleeves in terms of how we can dent this, kick it, slow it down to make sure it never happens,” it is likely the law will remain intact in a divided Congress, according to the Washington Post.
-
Obesity drug lorcaserin gets thumbs-down from FDA (Morning Read)
The Food and Drug Administration made it official Saturday, turning a thumbs-down to Lorqess (lorcaserin), the new diet drug by Arena Pharmaceuticals, because of concerns that it may cause tumors in rats and is marginally effective, according to the Pharmalot blog.
-
Do any doctors want to practice in rural America? (Morning Read)
A $1 billion effort by the Obama administration to relieve the physician shortage in rural America by subsidizing med school debt for young physicians is running up against a problem–not in attracting docs in the first place, but keeping them there once their initial three-to-five-year commitment is up.